Hengrui Medicine (600276.SH): HRS-8829 injection concentrated solution obtains the drug clinical trial approval notice.

Wisdom Financial APP News, Hengrui Medicine (600276.SH) announced recently that its subsidiary, Beijing Shengdi Medicine Co., Ltd., has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-8829 Injection Concentrated Solution. The company will soon conduct clinical trials.